<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapies for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) often achieve hematological responses but their impact on overall survival has generally not been evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>The Duesseldorf <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> Registry allowed us to perform matched-pair analyses to assess a possible survival benefit of treatment with thalidomide, <z:chebi fb="0" ids="39867">valproic acid</z:chebi>, low-dose Ara-C, antithymocyte globulin (ATG), induction chemotherapy, or allogeneic stem cell transplantation (allo-SCT) </plain></SENT>
<SENT sid="2" pm="."><plain>For <z:hpo ids='HP_0000001'>all</z:hpo> treatment modalities, lengthening of survival was restricted to certain subgroups of patients </plain></SENT>
<SENT sid="3" pm="."><plain>With the exception of allo-SCT, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treatment was generally palliative </plain></SENT>
<SENT sid="4" pm="."><plain>Recently, epigenetic treatment with demethylating agents proved to be the first therapy that can significantly prolong survival in patients with higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>